One-quarter of COVID-19 patients developed PTSD symptoms: a one-year longitudinal study

This study investigated the longitudinal development of PTSD symptoms and respiratory sequelae among COVID-19 patients one year after hospital discharge. The cumulative occurrence of probable PTSD in COVID-19 survivors (n=329) was 26.7%, which significantly decreased over the 12-month period (23.1% to 4.3%). Non-severe patients showed marked improvement in all four clusters of PTSD symptoms at 12 months compared to 3 months, while severe patients only showed improvements in re-experiencing and numbing symptoms. Moreover, being female and having respiratory sequelae increased the risk for chronic PTSD. Psychological interventions are required for COVID-19 patients during long-term convalescence.

One-quarter of COVID-19 patients developed PTSD symptoms: A one-year longitudinal study.

This study investigated the longitudinal development of PTSD symptoms and respiratory sequelae among COVID-19 patients one year after hospital discharge. The cumulative occurrence of probable PTSD in COVID-19 survivors (n = 329) was 26.7%, which significantly decreased over the 12-month period (23.1% to 4.3%). Non-severe patients showed marked improvement in all four clusters of PTSD symptoms at 12 months compared to 3 months, while severe patients only showed improvements in re-experiencing and numbing symptoms. Moreover, being female and having respiratory sequelae increased the risk for chronic PTSD. Psychological interventions are required for COVID-19 patients during long-term convalescence.

Beneficial for mental health, exercise more or less?

Regular physical activity may improve mental health during the pandemic by reducing inflammatory responses. However, overtraining or prolonged exercise training may adversely affect mental health.

Single-pass wind tunnel testing for recirculating virus aerosol control technologies

A number of recirculating flow aerosol control technologies have been commercialized to mitigate aerosol-transmitted virus infections. Many of these technologies incorporate filters for particle collection and some may also incorporate technologies for virus inactivation. Given the wide variety of commercially available aerosol control technologies to consumers, it is extremely important to develop standardized methods to characterize their performance in bioaerosol removal and inactivation, such that technologies can be compared on an “equivalent-test” basis. However, no standard procedures have been established to evaluate the effectiveness of bioaerosol removal and inactivation in recirculating aerosol control technologies. We propose the use of a single-pass tunnel to assess the performance of bioaerosol control technologies, as single-pass wind tunnels can be sealed with well-controlled velocity and particle concentration profiles. Here, we specifically describe the construction of a single-pass wind tunnel and apply it to three recirculating aerosol control technologies, incorporating UV-C sources, filters, and electrostatic precipitators, respectively. We utilize a porcine respiratory coronavirus (PRCV) challenge aerosol, generated via pneumatic nebulization of a high titer (∼107 TCID50 mL−1) viral suspension. Following guidelines similar to those used in the ANSI/ASHRAE Standard 52-2 test procedure for HVAC filters, in single-pass wind tunnel tests, velocity uniformity and particle uniformity are first monitored across the cross-section of the tunnel. The size distribution of viable particles is additionally determined in advance of tests by the collection of particles in the wind tunnel using a cascade impactor, with both RT-qPCR and titration used to quantify viruses collected on each impaction stage. We show that the viable particle size distribution follows the volumetric size distribution of the nebulized virus-laden suspension, and that this distribution can be tuned to be similar in shape to the observed distribution of aerosol from human respiratory activities. Following tunnel and virus aerosol characterization, for each tested technology, using triplicate tests, the single-pass log reduction based on RT-qPCR and viable virus titration is determined by simultaneously collecting virus aerosol particles upstream and downstream of the control technology. The tested technologies in this study have titration-based single-pass log reductions in the 1.5–4.0 range. Overall, design and testing suggest that the single-pass wind tunnel approach is a tractable method to examine the efficacy of aerosol control technologies in removing and inactivating viruses in aerosols, and suggest that such technologies should be described by their single-pass log reduction and operating flow rate, with the test virus size distribution reported alongside test results. In addition, we examine the limits of detection in single-pass wind tunnel tests in comparison to chamber tests, and in doing so find that for most control technologies, the wind tunnel test will yield higher concentrations downstream or during sampling, and hence clearer results for the log reduction.

The increase of PTSD in front-line health care workers during the COVID-19 pandemic and the mediating role of risk perception: a one-year follow-up study.

The long-term health consequences of the COVID-19 pandemic on health care workers (HCWs) are largely unclear. The purpose of the present study was to investigate the development of posttraumatic stress disorder (PTSD) in HCWs in a longitudinal manner. Additionally, we further explored the role of risk perception in the evolution of PTSD over time based on a one-year follow-up study. HCWs were recruited from hospitals in Guangdong, China. Demographic information, the PTSD checklist for DSM-5 (PCL-5) and the risk perception questionnaire were obtained online at two different time points: May to June 2020 (T1), with 317 eligible responses, and June 2021 (T2), with 403 eligible responses. Seventy-four HCWs participated in the survey at both T1 and T2. The results revealed that (1) the PTSD prevalence rate in the HCWs (cut-off = 33) increased from 10.73% at T1 to 20.84% at T2, and the HCWs reported significantly higher PTSD scores at T2 than at T1 (p < 0.001); (2) risk perception was positively correlated with PTSD (p < 0.001); and (3) PTSD at T1 could significantly positively predict PTSD at T2 (ß = 2.812, p < 0.01), and this longitudinal effect of PTSD at T1 on PTSD at T2 was mediated by risk perception at T2 (coefficient = 0.154, 95% CI = 0.023 to 0.297). Our data provide a snapshot of the worsening of HCWs' PTSD along with the repeated pandemic outbreaks and highlight the important role of risk perception in the development of PTSD symptoms in HCWs over time.

The prevalence and determinants of COVID-19 vaccine hesitancy in the age of infodemic.

BACKGROUND: Addressing COVID-19 vaccine hesitancy is key to ending the COVID-19 pandemic. Communication and media environments are potential drivers of vaccine hesitancy. It is worthwhile to examine the relationship between social media use and COVID-19 vaccine hesitancy. OBJECTIVE: This study aims to understand the prevalence and determinants of COVID-19 vaccine hesitancy. METHODS: Questionnaires were administered to 463 participants in mainland China. Factor analysis, correlation analysis, and linear regression models were utilized to examine the prevalence and influencing factors of COVID-19 vaccine hesitancy in China, as well as the relationship between social media use, media trust, health information literacy, and COVID-19 vaccine hesitancy. RESULTS: Lack of confidence and risk were identified as factors of COVID-19 vaccine hesitancy. Age, occupation status and income levels were significantly associated with COVID-19 vaccine hesitancy. In addition, we observed that frequency of social media use, diversity of social media use, media trust and health information literacy were significantly correlated with COVID-19 vaccine hesitancy. CONCLUSION: Increased frequency and diversity of social media use, media trust and health information literacy can mitigate COVID-19 vaccine hesitancy and promote COVID-19 vaccination.